"Designing Growth Strategies is in our DNA"
The global exocrine pancreatic insufficiency (EPI) therapeutics market size stood at USD 1.49 billion in 2018 and is projected to reach USD 2.55 billion by 2026, exhibiting a CAGR of 6.5% during the forecast period.
Exocrine pancreatic insufficiency refers to a medical condition which is characterized by the deficiency of the exocrine pancreatic enzymes. This deficiency results in maldigestion or the inability of the proper digestion of food. The diagnosis of exocrine pancreatic insufficiency is often purely clinical because the signs and symptoms of the disease often go undetected. This disease can often only be detected by a variety of diagnostic tests such as blood, stool, malabsorption, and pancreatic function tests.
In the current scenario, there are a number of positive factors providing major impetus to the exocrine pancreatic insufficiency therapeutics market trends. There is an increased awareness with respect to this disorder and the possible repercussions or negative impact if it is neglected. A number of chronic and serious disorders such as cystic fibrosis, celiac disease, and tumors are associated with exocrine pancreatic insufficiency.
Request a Free sample to learn more about this report.
One of the critical factors contributing to the growth of the global market is that several acute and chronic pancreatic disorders often lead to exocrine pancreatic insufficiency. Improved understanding of exocrine pancreatic insufficiency have contributed substantially to the introduction of new therapeutic measures and continued R&D by key market players. While the prevalence of exocrine pancreatic insufficiency in the general population is difficult to gauge, a number of key gastrointestinal disorders are linked to this disease. This is estimated to severely increase its prevalence in the global scenario, augmenting the exocrine pancreatic insufficiency therapeutics market growth.
“Increased Awareness and Innovation of Therapeutics is likely to Propel the Pancreatic Exocrine Insufficiency Treatment Market”
One of the crucial drivers for the global EPI therapeutics market growth is the increased awareness regarding exocrine pancreatic insufficiency and the corresponding effect on the overall health of the individual. For instance, acute pancreatitis is one of the leading gastrointestinal causes of hospital admission in the U.S. and causes a high prevalence of exocrine pancreatic insufficiency. Trends such as these are anticipated to drive the growth of the exocrine pancreatic insufficiency therapeutics market. For instance, in October 2019, AzurRx BioPharma announced that the first patients were dosed of its drug candidate MS1819-SD for exocrine pancreatic insufficiency.
“Increasing Prevalence of Associated Disorders to Drive the Market”
Other critical driving factors are the rising prevalence in associated disorder, leading to high prevalence of exocrine pancreatic insufficiency. Exocrine pancreatic insufficiency therapeutics have undergone major R&D innovations since the time they were initially introduced to the general public. A number of different clinical conditions of acute and serious nature have a high prevalence of exocrine pancreatic insufficiency. These include acute and autoimmune pancreatitis, cystic fibrosis, Shwachman–Diamond syndrome, and pancreatic tumors. These factors have led to the development of new therapeutics which has a number of advantages for the effective management of the disorder. Another key driving factor leading to the wide adoption of these therapies such as pancreatic enzyme replacement therapy (PERT) for the efficient treatment, due to increasing awareness resulting from the increasing prevalence of the disorder.
“The Pancreatic Enzyme Replacement Therapy (PERT) Segment to Generate Highest Growth Rate During the Forecast Period”
On the basis of therapy, the global market can be segmented into pancreatic enzyme replacement therapy (PERT), and nutritional therapy.
The PERT segment is estimated to hold the dominant share of the exocrine pancreatic insufficiency therapeutics market owing to their status as the conventional therapy. This is expected to enable the pancreatic enzyme replacement therapy to grow at the highest CAGR due to its positive features such as efficiency, efficacy, and potency in terms of treatment.
To know how our report can help streamline your business, Speak to Analyst
Nutritional therapy is also one of the critical components of the treatment regime for exocrine pancreatic insufficiency. This segment will hold a lower market share and will grow at a lower CAGR, but its importance cannot be undermined. This is because poor nutrition is expected to result in more complications and a higher mortality.
“Hospital Pharmacies Segment Likely to Hold the Highest Share among Distribution Channels.”
On the basis of distribution channel, the market for exocrine pancreatic insufficiency therapeutics can be segmented into hospital pharmacies, retail pharmacies & drug stores, and others. The hospital pharmacies segment is anticipated to have the dominant share because these medications are often prescribed by medical professionals at these institutions after due diagnostic measures.
Retail pharmacies & drug stores segment are anticipated to hold the second largest share because in terms of refilling prescriptions, these institutions are able to provide more efficient care. Retail pharmacies & drug stores segment are also anticipated to experience opportunities for revenue increase due to the increasing usage of online pharmacy facilities, which are often supported by these institutions.
North America generated a revenue of USD 1.18 billion in 2018 and is anticipated to emerge dominant in the global market during the forecast period. The rapid adoption of advanced therapeutics coupled with the usage of consistent and continued R&D across the region will drive the market growth in the region. Besides this, the increasing prevalence, coupled with the high awareness of associated gastrointestinal disorders, is expected to fuel the growth of the market in North America during the forecast period.
Asia Pacific is expected to witness the highest growth in terms of market value. Owing to the increasing disposable incomes across the region, there is a greater adoption of advanced therapeutics with respect to critical gastrointestinal disorders and its impact on overall health. For instance, Japan is one of the key countries across the world apart from North America and Europe to give population distributions of the disorder. This would drive the market growth across the region.
North America Exocrine Pancreatic Insufficiency Therapeutics Market Size, 2018
To get more information on the regional analysis of this market, Request a Free sample
On the other hand, Europe is projected to witness significant growth in the market due to the under penetration of the therapeutics. The high growth countries, including the U.K., France, and Germany would contribute to the growth of the market in Europe. The rest of the world market for exocrine pancreatic insufficiency therapeutics is anticipated to undergo a comparatively higher growth compared to the other key regions, due to the under penetration of the market where the revenue growth has not reached its complete potential and future growth prospects.
“Market Players like AbbVie, and Allergan Likely to Strengthen the Market Position across the Globe”
The exocrine pancreatic insufficiency therapeutics market is dominated by some key companies due to their strong product portfolio, key strategic decisions and dominance of market share. These includes a group of 2-3 key companies with wider geographic presence. But some new market players with new R&D is anticipated to result in strong regulatory approvals despite some recent setbacks in R&D. For instance, in April 2016, Anthera Pharmaceuticals announced that its product candidate Sollpura, a novel, non-porcine pancreatic enzyme replacement therapy failed its exocrine pancreatic insufficiency trial.
An Infographic Representation of Exocrine Pancreatic Insufficiency Market
To get information on various segments, share your queries with us
The increased awareness of exocrine pancreatic insufficiency and anticipated product launches based on new R&D is expected to fuel the exocrine pancreatic insufficiency therapeutics market growth.
Along with this, the report provides an elaborative analysis of the global market dynamics and competitive landscape. Various key insights presented in the report are the prevalence of major disorders associated with exocrine pancreatic insufficiency, pipeline analysis, recent industry developments such as mergers & acquisitions, regulatory scenario in crucial countries, and new product launches. Along with this, other key insights include overview of new R&D in exocrine pancreatic insufficiency treatment, key strategies adopted by market leaders, competitive landscape, and company profiles.
Value (USD billion)
By Distribution Channel
Fortune Business Insights says that the global market was valued at USD 1.49 billion in 2018 and is projected to reach USD 2.55 billion by 2026.
In 2018, the market was valued at USD 1.49 billion.
Growing at a CAGR of 6.5%, the market will exhibit steady growth in the forecast period (2019-2026)
Pancreatic Enzyme Replacement Therapy (PERT) segment is expected to be the leading segment in this market during the forecast period.
Increased healthcare awareness and strong product launches will drive the growth of the exocrine pancreatic insufficiency therapeutics market.
AbbVie and Allergan are the top players in the market.
North America is expected to hold the highest market share in the market.
Increased awareness, increasing R&D, increased prevalence of associated disorders and new product launches would drive the adoption of exocrine pancreatic insufficiency therapeutics.
Adoption of advanced exocrine pancreatic insufficiency therapeutics, new R&D, increased awareness, and increased prevalence of associated disorders are the hyper-market trends.
“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”- One of the Leading Food Companies in Germany
“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”- Intuitive Surgical
“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”- Major Food Company in Japan
“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”- Ziering Medical
“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”- Major Manufacturer of Precision Machine Parts in India
“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”- Hewlett-Packard
“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”- Global Management Consulting Firm
“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”- UK-based Start-up in the Medical Devices Sector
“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”- One of the Largest Companies in the Defence Industry